Giselle Castillo is the name of the Cartagena doctor who participates in the development of the vaccine for the American pharmaceutical company Pfizer, whose effectiveness was found to be 90% this week. (Read here: Pfizer and BioNTech announce 90% efficacy in their COVID vaccine)
Castillo is a graduate of the University of Cartagena’s medicine program and has postgraduate studies in tropical medicine, molecular epidemiology and translational medicine, all of which were completed at the University of Salamanca (Spain). She has been with Pfizer for four months and serves as the medical director in the department for vaccine research and development.
Its work consists mainly of monitoring and monitoring the clinical trials of the substance in order to guarantee its effectiveness in preventing the coronavirus.
Pfizer’s announcement about the high effectiveness of the vaccine was given just yesterday, when through a statement the company indicated that the results of its vaccine were even above those required by US regulators, something that would facilitate its authorization to start to be distributed.
“We have found that the vaccine is more than 90% effective in preventing COVID-19 in participants with no previous evidence of SARS-CoV-2 infection in the first interim tests,” the pharmaceutical company said in a statement.
The vaccine is in its phase 3 trials and its efficacy was confirmed seven days after the patients applied the second dose, that is, 28 days after the first. In this sense, the vaccine would require two injections, although the pharmacist noted that this may vary as the studies progress.
From Pfizer they indicated that they now expect to have two months of accumulated safety data in the third week of November in order to satisfy all the requirements of the United States Food and Drug Administration and begin the authorization process to distribute the vaccine, which It will have priority for health personnel, essential employees, the population at risk and areas with the highest risk of infection.
“Based on our projections, we expect to globally produce up to 50 million doses of the vaccine in 2020 and up to 1.3 billion doses in 2021,” Pfizer said in the statement.
* With information from EFE.